je.st
news
Zacks Investment Research Reaffirms "Buy" Rating for OncoGenex Pharmaceuticals Inc
2016-02-01 10:16:39| Biotech - Topix.net
's stock had its "buy" rating restated by Zacks Investment Research in a report released on Sunday, AnalystRatingsNetwork.com reports. They currently have a $0.75 target price on the biopharmaceutical company's stock.
Tags: inc
buy
research
rating
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||